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Abstract : Aim : The aim of the present study was to assess the changes in 
bone mineral density and bone turnover markers in long-term SERM.  Meth-
ods : The study was performed on 25 female outpatients with primary osteo-
porosis treated at the Osteoporosis Department of Showa University School 
of Medicine.  All patients had been on raloxifene （60 mg/day） for ≥ 3 years.  
The mean patient age was 67.1 years and the women were, on average, 18.4 
years postmenopausal.  Levels of bone turnover markers （urinary naltrexone 
［NTX］ and bone-specic alkaline phosphatase ［BAP］） and bone mineral den-
sity （BMD ; front lumbar vertebrae, three proximal femur sites, and two distal 
radius sites） were determined before and then annually after starting raloxifene 
for a period of 3 years.  Results : Over the 3-year treatment period, signicant 
decreases were seen in both urinary NTX and BAP levels.  Although BMD 
of the lumbar vertebrae and distal radius was increased over the 3 years after 
initiation of raloxifene treatment, the difference failed to reach statistical signi-
cance.  The BMD of the femoral neck decreased, whereas that of the femoral 
trochanter and femoral intertrochanter area increased.  Conclusions : The 
selective estrogen receptor modulator raloxifene is suitable for the treatment of 
osteoporosis in postmenopausal patients because it reduces bone turnover while 
maintaining adequate bone density.
Key words : raloxifene, SERM : selective estrogen receptor modulator, bone 
mineral density
Introduction
　In Japan, osteoporosis can be treated with bisphosphonates, selective estrogen receptor 
modulators （SERMs）, parathyroid hormone （PTH）, or calcitonin.  Bisphosphonates improve 
bone mineral density （BMD） and inhibit bone resorption.  However, there are some limita-
tions associated with their use : patients have to take the drug soon after waking up, they 
must avoid lying down for at least 30 min, and they need to take the drug with approxi-
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mately 180 mL water.  There are no such limitations imposed on the use of SERMs, making 
these drugs the preferred treatment option for osteoporosis.  SERMs have been reported 
to increase the formation of collagen cross-links and to improve bone mineral properties1，2）. 
However, only postmenopausal women can be administered SERMs, and physicians are 
required to select other drugs for the treatment of osteoporosis in men or premenopausal 
women.  Compared with bisphosphonates, such as alendronate and risedronate, SERMs only 
slightly improve markers of bone turnover.  In the present study, to evaluate the efcacy 
of SERM treatment, we investigated changes in multiple markers of bone turnover, as well 
as BMD at different sites, over a 3-year period in women who had been on the SERM 
raloxifene for at least 3 years beginning in 2007.
Methods
Subjects
　The subjects of the present study were 25 women who were attending the Osteoporosis 
Outpatient Unit of Showa University Hospital for the treatment of postmenopausal osteo-
porosis.  All women had been on raloxifene （60.0 mg/day） for＞ 3 years.  The mean age 
of the women was 67.1 years （range 54-84 years）, and they were, on average, 18.4 years 
postmenopausal （range 3-36 years）.
Methodology
　Markers of bone turnover （urinary cross-linked N-terminal telopeptides of type I collagen 
［NTX］ and bone-specic alkaline phosphatase ［BAP］） and BMD were determined in each 
patient before and then annually after starting raloxifene treatment.  BMD was measured in 
the anteroposterior lumbar spine, the proximal femur （neck, intertrochanter, and trochanter）, 
and the ultradistal radius （the ultradistal radius and distal one-third of the radius） by dual 
energy X-ray absorptiometry （Discovery A ; Hologic, Bedford, MA, USA）.
Statistical analysis
　Data are presented as the mean ± SD.  Values obtained prior to initiating treatment were 
considered as reference （baseline） values.  Differences were analyzed using Student’s t-test, 
with P＜ 0.05 considered signicant.  All analyses were performed using Stat Mate III ver.  
3.14 （ATMS, Tokyo, Japan）.
Ethical considerations
　This study was approved by the Ethics Committee of Showa University School of 
Medicine （Approval No. 1169）.  All patients provided written informed consent prior to 
participating in the study.
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Results
Markers of bone turnover
　Prior to starting raloxifene treatment, mean urinary NTX levels in the 25 women were 
61.9 ± 32.6 nmol bone collagen equivalents （BCE）/mmol creatinine （Cr）.  After 1, 2, and 3 
years treatment, urinary NTX levels were 44.3 ± 27.4, 41.7 ± 26.9, and 38.5 ± 17.5 nmol BCE/
mmol Cr, respectively （P＜ 0.01, P＜ 0.01, and P＜ 0.001 compared with baseline, respec-
tively）.  As indicated in Fig. 1, urinary NTX levels decreased signicantly from 1 year after 
initiation of raloxifene treatment.
　Prior to raloxifene treatment, baseline BAP levels were 29.0 ± 15.0μg/L.  After 1, 2, 
and 3 years of treatment, BAP levels had decreased to 24.3 ± 11.3, 23.4 ± 10.3, and 20.8 ±
11.1μg/L, respectively （P＜ 0.05, P＜ 0.01, and P＜ 0.001 compared with baseline, respec-
tively）.  As for urinary NTX levels, BAP levels started to decrease signicantly from 1 year 
after the start of raloxifene treatment （Fig. 2）.
Bone mineral density （Table 1）
　There were no significant changes in the BMD of L2-L4 over the 3-year treatment 
period （Fig. 3a）.  Most importantly, none of the patients experienced any new compression 
fractures over this time.
　In the proximal femur, there were signicant decreases in the BMD of the femoral neck 
Fig. 1.  Urinary levels of type I collagen cross-linked 
N-telopeptides （NTX） before and after 1, 
2, and 3 years of treatment with raloxifene 
（60.0 mg/day）. There was a signi ficant de crease 
in NTX levels after 1 year, and although 
there was a tendency for levels to de crease in 
subsequent years, values were main tained at 
around 40 bone collagen equivalents （BCE）/
mmol creatinine （Cr）.
Data are the mean ± SD., ＊＊P＜ 0.01, ＊＊＊P＜ 
0.001 compared with baseline （before treat-
ment） values.
Fig. 2.  Changes in bone-specific alkaline phosphatase 
（BAP） before and after 1, 2, and 3 years 
of treatment with raloxifene （60.0 mg/day）. 
Significant decreases （20-25μg/L） were 
observed beginning 1 year after the initiation 
of therapy.
Data are the mean ± SD. ＊P＜0.05, ＊＊P＜0.01, 
＊＊＊P ＜ 0.001 compared with baseline （before 
treatment） values.
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after 2 and 3 years of treatment with raloxifene, but not after 1 year （Fig. 3b）.  In contrast, 
the BMD of the femoral trochanter and intertrochanter increased signicantly over the treat-
ment period （Fig. 3c, d）.
　Finally, raloxifene treatment had no signicant effect on the BMD of the ultradistal radius 
or the distal one-third of the radius （Fig. 3e, f）.
Discussion
　Raloxifene, a SERM, is a member of the benzothiophene family that does not have 
a steroidal backbone.  It inhibits bone resorption without affecting the endometrium and 
Table 1  Bone mineral density at various sites before （baseline） and after 1, 2, 
and 3 years of treatment with raloxifene.
Bone mineral density
 (mg/cm2 ) P-value＊
Anteroposterior lumbar spine （L2-L4）
　Baseline 0.730 ± 0.141
　1 year 0.730 ± 0.155 0.97
　2 years 0.728 ± 0.154 0.78
　3 years 0.738 ± 0.164 0.46
Proximal femur
　Femoral neck
　　Baseline 0.549 ± 0.070
　　1 year 0.538 ± 0.082 0.89
　　2 years 0.528 ± 0.097 P＜ 0.05
　　3 years 0.521 ± 0.093 P＜ 0.05
　Femoral trochanter
　　Baseline 0.453 ± 0.072
　　1 year 0.476 ± 0.091 P＜ 0.05
　　2 years 0.504 ± 0.071 P＜ 0.01
　　3 years 0.499 ± 0.077 P＜ 0.001
　Intertrochanter
　　Baseline 0.717 ± 0.108
　　1 year 0.727 ± 0.128 0.34
　　2 years 0.746 ± 0.125 P＜ 0.05
　　3 years 0.754 ± 0.132 P＜ 0.01
Ultradistal radius
　Baseline 0.306 ± 0.076
　1 year 0.304 ± 0.076 0.87
　2 years 0.301 ± 0.065 0.68
　3 years 0.294 ± 0.062 0.17
Distal one-third of the radius
　Baseline 0.462 ± 0.083
　1 year 0.460 ± 0.079 0.89
　2 years 0.459 ± 0.079 0.80
　3 years 0.467 ± 0.068 0.51
Data show the mean ± SD.
＊P-values are for comparisons with baseline values.
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Fig. 3.  Changes in the bone mineral density （BMD of （a） the second to fourth lumbar vertebrae （L2-L4）, 
（b） femoral neck, （c） femoral trochanter （troch）, （d） intertrochanteric area, （e） ultradistal radius, and 
（f） distal one-third of the radius before and after 1, 2, and 3 years of treatment with raloxifene （60 mg/
day）.  Significant increases were seen in the BMD of the femoral trochanter and intertrochanteric area, 
whereas the BMD of the femoral neck decreased significantly after 2 and 3 years of treatment.
Data are the mean ± SD. ＊P＜ 0.05, ＊＊P＜ 0.01, ＊＊＊P＜ 0.001 compared with baseline （before treatment） 
values.
（a） （b）
（c） （d）
（e） （f）
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increases bone mass 3）.  The side effects of raloxifene include hot ashes, sweating, dizzi-
ness, gastrointestinal disorders, and edema or convulsions of the lower limbs4，5）.  In Showa 
University Hospital, we have also observed mild symptoms, such as breast enlargement ; 
however, no serious side effects, such as deep vein thrombosis, have been encountered.
　There are several options for the treatment of osteoporosis, including active vitamin D3, 
vitamin K2, and calcium, as well as bisphosphonates, SERMs, and PTH.  Treatment for 
osteoporosis needs to be tailored to meet individual patient requirements.  For example, 
bisphosphonates, SERMs, and calcitonin inhibit bone resorption, whereas PTH promotes 
bone formation.  To determine the best treatment regimen for our patients, we perform sim-
ple X-ray examinations of the thoracic and lumbar vertebrae ; biochemical tests of the blood 
and urine ; measure BMD of the lumbar vertebrae, femur, and radius ; and determine levels 
of bone turnover markers and PTH.  These examinations provide information regarding the 
presence or absence of vertebral fractures, as well as the number of fractures if present ; the 
young/adult ratio of BMD ; whether bone turnover is high or low ; whether serum calcium, 
phosphorus, and magnesium levels are in the normal range ; and the presence or absence 
of parathyroid dysfunction.  Using this information, we develop therapeutic strategies for 
individual patients and determine the need for further referral to a physician or obstetrician.
　In 2000, the US National Institutes of Health dened bone strength as 70% BMD and 
30% ossein 6）.  Bone turnover, microstructure, microfracture, and calcication are the factors 
contributing to ossein.  Of these, bone turnover is the most easily measured in clinical 
practice using markers of bone turnover 7，8）, such as NTX levels in the blood and urine, 
BAP, tartrate-resistant acid phosphatase-5b, and N-propeptide of type I procollagen.  Under-
carboxylated osteocalcin （ucOC） is another marker of bone turnover that can be used as 
an index of sufcient vitamin K levels in the blood.  If blood ucOC levels are high, vitamin 
K2 may be administered.  Furthermore, levels of pentosidine or homocysteine can be used 
as predictors of vertebral fractures 9）.  Although these measures provide clinically important 
information, they are currently not covered by osteoporosis insurance in Japan, which is an 
issue that needs to be resolved.
　In the present study, raloxifene decreased NTX by 28% over the course of 1 year.  In 
another study, we found that alendronate decreased NTX by 66% over the course of 1 
year 10）.  In the present study, raloxifene signicantly decreased both urinary NTX （a marker 
of bone resorption） and BAP （a marker of bone formation）, and inhibited bone turnover. 
We did not observe atypical femur fractures 11，12） or jaw osteonecrosis 13）, which have been 
reported previously as complications associated with the use of bisphosphonates, and this 
may be due to the lower potency of raloxifene.  If signicant inhibition of bone resorption 
markers is necessary, then bisphosphonates are the better choice ; however, in patients under-
going dental treatment, those exhibiting only slightly enhanced levels of bone resorption 
markers, or in those who are recovering from fractures （i.e. those in whom bone turnover 
should not be excessively inhibited）, it is preferable to use SERMs.
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　There were no significant decreases in the BMD of the lumbar vertebrae or radius. 
However, there was a decrease in the BMD of the femoral neck and an increase in the 
BMD of the femoral trochanter.  The femoral trochanter has more spongy bone than the 
femoral neck 14）, which may explain the increase in BMD in the trochanter over the course 
of drug treatment.  According to a bridging study of raloxifene conducted in Japan 4）, the 
BMD of the lumbar vertebrae in the raloxifene-treated group was signicantly higher than 
that of the placebo-treated group after 24 weeks, with the former group also exhibiting 
a signicantly higher mean increase in BMD after 1 year of treatment （3.5%）.  In the 
multiple outcomes of raloxifene evaluation （MORE） trial, the BMD of the lumbar verte-
brae and femoral neck increased by 2.6% and 1.3%, respectively, signicantly higher than 
that in the placebo-treated group 15）.  No signicant differences of the BMD of the lumbar 
vertebrae were observed between before administration and after 3 years in the present 
study, although there was a tendency for the BMD of the lumbar vertebrae to increase with 
treatment.  The radius is not a weight-bearing bone and is not easily affected by mechanical 
stress.  Wiping the oor with hands is a good exercise for the radius ; however, modern 
lifestyles offer few opportunities to perform such tasks.  We recommend that people perform 
intentional weight-bearing exercises for the radius （e.g. wall-pushing exercise） and femoral 
neck （e.g. standing on one leg with the eyes open）16）, both of which contain cortical bone.
　In conclusion, in the present study we examined the effects of raloxifene, a SERM, on 
BMD and markers of bone turnover over a 3-year period.  During this time, there was 
a signicant decrease in markers of bone turnover.  Although there was a tendency for 
increased BMD of the lumbar vertebrae over the same period, the differences failed to 
reach statistical signicance.  Thus, raloxifene appears to be suitable for use in postmeno-
pausal women in whom bone turnover needs to be decreased gradually while BMD is 
maintained.
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